BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 18798255)

  • 1. Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer.
    Moreau D; Jacquot C; Tsita P; Chinou I; Tomasoni C; Juge M; Antoniadou-Vyza E; Martignat L; Pineau A; Roussakis C
    Int J Cancer; 2008 Dec; 123(11):2676-83. PubMed ID: 18798255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment.
    Rousseau B; Jacquot C; Le Palabe J; Malleter M; Tomasoni C; Boutard T; Sakanyan V; Roussakis C
    Sci Rep; 2015 May; 5():10356. PubMed ID: 26011298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
    Ling C; Chen G; Chen G; Zhang Z; Cao B; Han K; Yin J; Chu A; Zhao Y; Mao X
    Int J Cancer; 2012 Nov; 131(10):2411-9. PubMed ID: 22362357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.
    Lee CJ; Yue CH; Lin YJ; Lin YY; Kao SH; Liu JY; Chen YH
    Anticancer Res; 2014 Nov; 34(11):6467-72. PubMed ID: 25368247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.
    Lee HJ; Latif M; Choe H; Ali I; Lee HK; Yang EH; Yun JI; Chae CH; Jung JK; Kim HR; Lee CO; Park CH; Lee K
    Arch Pharm Res; 2014; 37(9):1130-8. PubMed ID: 24446111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
    Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
    Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
    Kong M; Fan J; Dong A; Cheng H; Xu R
    Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
    Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
    Mousa SA; Yalcin M; Bharali DJ; Meng R; Tang HY; Lin HY; Davis FB; Davis PJ
    Lung Cancer; 2012 Apr; 76(1):39-45. PubMed ID: 22024450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt/β-catenin signaling inhibition.
    Bi X; Xia X; Mou T; Jiang B; Fan D; Wang P; Liu Y; Hou Y; Zhao Y
    Eur J Pharmacol; 2014 Nov; 742():145-52. PubMed ID: 25199964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
    DeCicco KL; Tanaka T; Andreola F; De Luca LM
    Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
    Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
    Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk J; Rolff J; Becker M; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
    Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
    Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.